W.D. Tap Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

Patent citations

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (5)

4× Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2× Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, United States of America
1× 11Memorial Sloan Kettering Cancer Center, New York, NY, USA
1× Department of Medical Oncology, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America
1× Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA

Papers 9 stored

All · Aachen affiliation only

151P Phase III study of ivosidenib vs placebo in isocitrate dehydrogenase 1 (IDH1)-mutant conventional chondrosarcoma (CHONQUER): Frequency of IDH1 mutation by clinical factors
2026 ESMO rare cancers. article Medicine Bone Tumor Diagnosis and Treatments Open access

0

citations
111P Pooled safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior colony-stimulating factor 1 receptor (CSF1R) inhibitor therapy
2026 ESMO rare cancers. article Medicine Musculoskeletal synovial abnormalities and treatments Open access

0

citations
2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial
2025 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access

1

citations
LBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
2024 Annals of Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments Open access

1

citations
1769P Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
2024 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access

0

citations
CO22 Health-Related Quality of Life from a Phase 4 Global Clinical Study to Evaluate Discontinuation and Rechallenge of Pexidartinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) Previously Treated with Pexidartinib
2024 Value in Health conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments Open access

0

citations
P63 Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study
2022 Value in Health conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments Open access cited by 11 patents

6

citations
475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
2022 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access cited by 12 patents

3

citations
1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion
2022 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access

5

citations

9 results

W.D. Tap ▲ Sign in to save

Departments & institutes in Aachen

Papers 9 stored

W.D. Tap Sign in to save